The Emerging Role of H3K9me3 as a Potential Therapeutic Target in Acute Myeloid Leukemia.

Monaghan, Laura; Massett, Matthew E; Bunschoten, Roderick P; Hoose, Alex; Pirvan, Petrisor-Alin; Liskamp, Robert M J; Jørgensen, Heather G; Huang, Xu

Monaghan, Laura; Massett, Matthew E; Bunschoten, Roderick P; Hoose, Alex; Pirvan, Petrisor-Alin; Liskamp, Robert M J; Jørgensen, Heather G; Huang, Xu.

Afiliación

Monaghan L; Haemato-Oncology/Systems Medicine Group, Paul O'Gorman Leukemia Research Center, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
Massett ME; Haemato-Oncology/Systems Medicine Group, Paul O'Gorman Leukemia Research Center, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
Bunschoten RP; School of Chemistry, University of Glasgow, Glasgow, United Kingdom.
Hoose A; School of Chemistry, University of Glasgow, Glasgow, United Kingdom.
Pirvan PA; School of Chemistry, University of Glasgow, Glasgow, United Kingdom.
Liskamp RMJ; School of Chemistry, University of Glasgow, Glasgow, United Kingdom.
Jørgensen HG; Haemato-Oncology/Systems Medicine Group, Paul O'Gorman Leukemia Research Center, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
Huang X; Haemato-Oncology/Systems Medicine Group, Paul O'Gorman Leukemia Research Center, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Front Oncol ; 9: 705, 2019.

Article en En | MEDLINE | ID: mdl-31428579

Palabras clave

Histone 3 lysine 9 trimethylation (H3K9me3); Leukaemic stem cell (LSC); acute myeloid leukemia (AML); gene suppression; heterochromatin; lysine specific demethylase (KDM)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: Front Oncol Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google